Re: Liver test 2X normal is OK?
- From: Susan <nevermind@xxxxxxxxxx>
- Date: Tue, 06 Dec 2005 14:25:20 -0500
x-no-archive: yes
John Merlino wrote: 1: Minerva Med. 1990 Jun;81(6):475-9. Related Articles, Links
[Evaluation of the cholesterol-lowering effectiveness of pantethine in women in perimenopausal age]
[Article in Italian]
Binaghi P, Cellina G, Lo Cicero G, Bruschi F, Porcaro E, Penotti M.
Servizio di Cardiologia, Istitut Clinici di Perfezionamento, Milano.
Cardiovascular diseases are the main cause of death also in women. Their incidence, rapidly growing in the peri-menopausal period, is related to serum levels of total cholesterol and its LDL fraction. It was also shown that the peroxidation of LDL is an additional factor in the genesis of atherosclerotic vascular disease. As long-term treatments with synthetic lipid-lowering drugs may cause undesirable side effects, while pantethine is known to be well tolerated, we treated 24 hypercholesterolemic women (total serum cholesterol greater than or equal to 240 mg/dl), in perimenopausal age (range: 45-55 years, mean +/- SD = 51.6 +/- 2.4) with 900 mg/day of pantethine. This is a precursor of coenzyme A, with an antiperoxidation effect in vivo, and our aim was to confirm its lipid lowering activity in this particular type of patients. After 16 weeks of treatment, significant reductions of total cholesterol, LDL-cholesterol and LDL-C/HDL-C ratio could be observed. No remarkable changes of the main laboratory parameters (fasting blood sugar, B.U.N., creatinine, uric acid) were seen. Efficacy percentages of the treatment were about 80%. None of the patients complained of adverse reactions due to the treatment with pantethine. In conclusion, we suggest that pantethine should be considered in the long-term treatment of lipid derangements occurring in the perimenopausal age.
PMID: 2359503 [PubMed - indexed for MEDLINE] 1: Acta Biomed Ateneo Parmense. 1984;55(1):25-42. Related Articles, Links
[Hyperlipidemia, diabetes and atherosclerosis: efficacy of treatment with pantethine]
[Article in Italian]
Arsenio L, Caronna S, Lateana M, Magnati G, Strata A, Zammarchi G.
The hypolipidemizing effects of Pantethine were investigated by the Authors in 37 hypercholesterolemic and/or hypertriglyceridemic patients. Of these, 21 were also diabetic, in a satisfying glucidic compensation, in order to verify the action of this drug also in this metabolic condition. The study was carried out for three months and during this period the patients were given Pantethine at the dose of 600 mg/die orally. At the 30th, the 60th, the 90th day of treatment the following parameters were controlled: cholesterolemia, HDL cholesterol, apolipoproteins A and B, triglyceridemia, systolic and diastolic arterial pressure, uricemia, body weight. Thirty days after suspending the treatment, the parameters were controlled again to detect a possible "rebound" effect. The results were analyzed on the whole case-record, subdividing the patients in dislipidemic and diabetic-dislipidemic, and on the basis of the Fredrickson's classification. Pantethine induced in all groups a quick and progressive decrease of cholesterolemia, triglyceridemia, LDL cholesterol and Apolipoproteins B with increased HDL cholesterol and Apolipoproteins A. After suspending the treatment, there is a clear inversion of the state of these parameters. The Authors conclude that the present work shows that Pantethine, a natural and atoxic substance, an important component of Coenzyme A, is efficacious in determining a clear tendency towards normalization of the lipidic values.
PMID: 6232801 [PubMed - indexed for MEDLINE] 1: Atherosclerosis. 1984 Jan;50(1):73-83. Related Articles, Links
Controlled evaluation of pantethine, a natural hypolipidemic compound, in patients with different forms of hyperlipoproteinemia.
Gaddi A, Descovich GC, Noseda G, Fragiacomo C, Colombo L, Craveri A, Montanari G, Sirtori CR.
Pantethine (P), the stable disulphate form of pantetheine, major component and precursor of coenzyme A, was evaluated within a double-blind protocol (8 weeks for P or for a corresponding placebo) in 29 patients, 11 with type IIB hyperlipoproteinemia, 15 with type IV, and 3 with an isolated reduction of high density lipoprotein cholesterol (HDL-C) levels. In type IIB patients, P (300 mg t.i.d.) determined a highly significant lowering of plasma total and low density lipoprotein (LDL) associated cholesterol (-13.5% for both parameters). In the same patients, HDL-C levels increased about 10% at the end of treatment. Switching from P to placebo was associated with a rapid return to the baseline cholesterolemia. Both in type IIB and type IV patients, plasma triglyceride levels were reduced around 30%, when P was given as the first treatment; when it was preceded by placebo, reductions were less striking (respectively, -17.8% for type IIB and -13.0% for type IV, at the end of P treatment). HDL-C levels were not increased by P, either in type IV, and in the patients with low HDL cholesterolemia. In type IV, LDL cholesterol levels showed a variable response to P: they tended to increase when below 132 mg/dl, prior to treatment, and to be reduced when above this level. This study provides evidence for a significant hypocholesterolemic effect of P, a natural compound free of overt side effects. It also indicates that P may raise HDL-C levels in type IIB patients, while moderately reducing triglyceridemia.
Publication Types: • Clinical Trial • Controlled Clinical Trial
PMID: 6365107 [PubMed - indexed for MEDLINE]
1: Int J Clin Pharmacol Ther Toxicol. 1986 Nov;24(11):630-7. Related Articles, Links
Lipoprotein changes induced by pantethine in hyperlipoproteinemic patients: adults and children.
Bertolini S, Donati C, Elicio N, Daga A, Cuzzolaro S, Marcenaro A, Saturnino M, Balestreri R.
Following a brief outline of current knowledge concerning atherosclerosis and its treatment, the authors describe the results obtained by treating with pantethine (900-1200 mg daily for 3 to 6 months) a series of 7 children and 65 adults suffering from hypercholesterolemia alone or associated with hypertriglyceridemia (types IIa and IIb of Fredrickson's classification). Pantethine treatment produced significant reduction of the better known risk factors (total cholesterol, LDL-cholesterol, triglycerides, and apo-B) and a significant increase of HDL-cholesterol (signally HDL2) and apolipoprotein A-I. The authors conclude with a discussion of these results and of the possible role of pantethine in the treatment of hyperlipoproteinemia, in view of its perfect tolerability and demonstrated therapeutic effectiveness.
PMID: 3098691 [PubMed - indexed for MEDLINE] : Atherosclerosis. 1984 Dec;53(3):255-64. Related Articles, Links
Pantethine reduces plasma cholesterol and the severity of arterial lesions in experimental hypercholesterolemic rabbits.
Carrara P, Matturri L, Galbussera M, Lovati MR, Franceschini G, Sirtori CR.
Pantethine (P), a coenzyme A precursor, was administered to cholesterol-fed rabbits (0.5% cholesterol diet + 1% pantethine) for 90 days. At the end of treatment, plasma total cholesterol levels were reduced 64.7% and the HDL/total cholesterol ratio increased in P-treated animals; a significant rise of the apo A-I/A-II ratio was detected in HDL. VLDL lipid and protein levels were, on the other hand, reduced by P. The cholesterol-ester content of both liver and aortic tissues was not significantly affected by P. Although the total aortic area with evident plaques was reduced only 18.2%, the microscopical examination of sections from the major vessels of P-treated animals, showed a reduction in the severity of lesions, both in the aorta and in the coronary arteries. These findings suggest that P, in addition to significantly lowering plasma cholesterol levels in rabbits on an experimental diet, may modify lipid deposition in major arteries, possibly by affecting lipoprotein composition and/or exerting an arterial protective effect.
PMID: 6442152 [PubMed - indexed for MEDLINE] Clin Ther. 1986;8(5):537-45. Related Articles, Links
Effectiveness of long-term treatment with pantethine in patients with dyslipidemia.
Arsenio L, Bodria P, Magnati G, Strata A, Trovato R.
A one-year clinical trial with pantethine was conducted in 24 patients with established dyslipidemia of Fredrickson's types II A, II B, and IV, alone or associated with diabetes mellitus. The treatment was well tolerated by all patients with no subjective complaints or detectable side effects. Blood lipid assays repeated after 1, 3, 6, 9, and 12 months of treatment revealed consistent and statistically significant reductions of all atherogenic lipid fractions (total cholesterol, low-density lipoprotein cholesterol, and apolipoprotein B) with parallel increases of high-density lipoprotein cholesterol and apolipoprotein A. The results were equally good in patients with uncomplicated dyslipidemia and in those with associated diabetes mellitus. The authors conclude that pantethine (a drug entity related to the natural compound, pantetheine) represents a valid therapeutic support for patients with dyslipidemia not amenable to satisfactory correction of blood lipids by diet alone.
PMID: 3094958 [PubMed - indexed for MEDLINE] Acta Biomed Ateneo Parmense. 1987;58(5-6):143-52. Related Articles, Links
[Clinical use of pantethine by parenteral route in the treatment of hyperlipidemia]
[Article in Italian]
Arsenio L, Bodria P, Bossi S, Lateana M, Strata A.
Servizio di Malattie del Ricambio e Diabetologia, Ospedali Riuniti, Parma.
Recent investigations have confirmed the effectiveness and the excellent tolerability of pantethine, a derivative of pantetheine, an essential part of the acetylation coenzyme CoA, administered P.O., in normalizing the blood lipid concentrations of patients with hyperlipidemias. A group of 18 patients with hyperlipidemias (9 M, 9 F), with an average age of 52.6 years, was submitted to pantethine parenteral treatment. After a 20 days wash-out, pantethine (400 mg/day; BID) was administered intramuscularly, for 20 days. Total cholesterol, triglycerides, HDL-cholesterol, apo A-1 and B lipoprotein, uric acid in serum, glycemia, CBC, B.U.N., creatininemia, E.S.R., SGOT, SGPT, bilirubinemia, cardiac frequency, blood pressure and body weight were controlled before and after treatment. The drug showed to have a therapeutic effectiveness by a rapid and significant improvement in the blood lipid pattern with reduction of total cholesterol, triglycerides and apo-B lipoprotein and increase of HDL-cholesterol and apo A-1 lipoprotein. The tolerability of pantethine at the stated dosage and mode of administration was invariably excellent, with non complaints or visible side effects imputable to the test drug. BUN, creatininemia, glycemia, SGOT, SGPT, bilirubinemia, E.S.R., CBC, cardiac frequency and blood pressure readings showed no noteworthy changes throughout the study.
PMID: 2970754 [PubMed - indexed for MEDLINE]
: Acta Biomed Ateneo Parmense. 1987;58(5-6):143-52. Related Articles, Links
[Clinical use of pantethine by parenteral route in the treatment of hyperlipidemia]
[Article in Italian]
Arsenio L, Bodria P, Bossi S, Lateana M, Strata A.
Servizio di Malattie del Ricambio e Diabetologia, Ospedali Riuniti, Parma.
Recent investigations have confirmed the effectiveness and the excellent tolerability of pantethine, a derivative of pantetheine, an essential part of the acetylation coenzyme CoA, administered P.O., in normalizing the blood lipid concentrations of patients with hyperlipidemias. A group of 18 patients with hyperlipidemias (9 M, 9 F), with an average age of 52.6 years, was submitted to pantethine parenteral treatment. After a 20 days wash-out, pantethine (400 mg/day; BID) was administered intramuscularly, for 20 days. Total cholesterol, triglycerides, HDL-cholesterol, apo A-1 and B lipoprotein, uric acid in serum, glycemia, CBC, B.U.N., creatininemia, E.S.R., SGOT, SGPT, bilirubinemia, cardiac frequency, blood pressure and body weight were controlled before and after treatment. The drug showed to have a therapeutic effectiveness by a rapid and significant improvement in the blood lipid pattern with reduction of total cholesterol, triglycerides and apo-B lipoprotein and increase of HDL-cholesterol and apo A-1 lipoprotein. The tolerability of pantethine at the stated dosage and mode of administration was invariably excellent, with non complaints or visible side effects imputable to the test drug. BUN, creatininemia, glycemia, SGOT, SGPT, bilirubinemia, E.S.R., CBC, cardiac frequency and blood pressure readings showed no noteworthy changes throughout the study.
PMID: 2970754 [PubMed - indexed for MEDLINE]
TC: 148 HDL: 35 LDL: 96 Triglycerides: 86
I had a bypass 7 years ago. I am not diabetic and never had a heart attack.
During my visit with the cardiologist today, he wanted to increase my 10 mg
of Zocor to 20 mg. I suggested we wait until the next blood test to allow
me to get back on the diet and treadmill, which I started again just over 2
weeks ago. He said if my LDL is over 75, he is going to up my Zocor to 20
mg. My liver test result this time was 2 points below the maximum and that
prompted me to inquire about the danger of increasing Zocor. Apparently my
cardiologist is not concerned even if the liver test is twice the normal
range as long as there are no symptoms, and I guess that means muscle pain.
Opinions?
I'd ask what % of your LDL is the injurious VLDL, first of all. Second of all, I'd discuss the following info with your doctor, since this commonly used lipid therapy (Europe, Japan) is highly effective and completely safe even in dialysis and hepatitis patients. It lowered my LDL 70 points in 3 mos, and my HDL went up at the same time. Cutting dietary starches and replacing with veggies and olive oil has been demonstrated to improve CVD serum markers, too.
.
- Follow-Ups:
- Re: Liver test 2X normal is OK?
- From: Susan
- Re: Liver test 2X normal is OK?
- References:
- Liver test 2X normal is OK?
- From: John Merlino
- Liver test 2X normal is OK?
- Prev by Date: Liver test 2X normal is OK?
- Next by Date: Folate linked to DHA status
- Previous by thread: Liver test 2X normal is OK?
- Next by thread: Re: Liver test 2X normal is OK?
- Index(es):
Relevant Pages
|
